Ann: Investor Presentation Imugene Arovella Therapies, page-11

Is it worth to invest LT in ALA on the back of yesterday's ann.?

I have to be honest, last year I didn't care about ALA-101 because I had not much trust in MB and no idea about iNKT. That has changed due to my exposure to NK cells at CHM and the fact that IMU's SAB must have seen something valuable and worth to progress.

The current advantage of CHM, RAD and ALA is the small number of SOI compared to IMU, causing a low valuation at even higher sp levels and much less liquidity to sell into any future rise.

With any pre-clinical result 12-18 months away I have started to build a solid share holding to take advantage of hopefully higher sp, maybe 10c + in 1-2 years time. Current sp level might scare existing holders but provide a good opportunity for new LTers.

GLTA